Loading...

GTBP GT BIOPHARMA INC Management Changes 8-K Filing

GT B

GTBP

GT BIOPHARMA INC

(GTBP)

2024 8-K

Show Summary

Summary

Equity Offerings

Equity Offerings

Equity Offerings

Warrant Issuance

Warrant Inducement

First Patient Dosed

Nasdaq Compliance

Clinical Trial Agreement

Management Change

FDA Clearance of IND Applic...

Annual Meeting Vote Results

Management Change

Purchase Agreement and Priv...

Amendment to Settlement and...

Reverse Stock Split

Special Meeting of Stockhol...

IND Application for GTB-3650

Notice of Delisting

Departure and Appointment o...

Purchase Agreement

External Links:

Dr. Jeffrey Miller has changed his title from Consulting Chief Medical Officer and Consulting Chief Scientific Officer to Consulting Senior Medical Director effective September 16, 2024, to align with University of Minnesota policies amid a Phase I clinical trial for GTB-3650.

AI Assistant

GT BIOPHARMA INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.